ArticleTranslational cancer research2025
Stratifying prognosis in stage III colorectal cancer patients: the role of tumor deposits and lymph node ratio.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The combined effect of tumor deposition (TD) and positive lymph node ratio (LNR) in colorectal cancer (CRC) is unknown. The aim of this study was to investigate the effects of TD and LNR in the prognosis of postoperative CRC patients. Methods: We retrospectively reviewed 42,701 stage III CRC patients, including 42,470 patients from the Surveillance, Epidemiology, and End Results (SEER) database as a training set, and 231 patients from our hospital as a validation set. We analyzed the relationship of TD and LNR with overall survival (OS) by the Kaplan-Meier method and Cox regression analyses. Results: Both TD-positive and high LNR (value ≥0.31) were related to worse OS in the training [hazard ratio (HR), 1.518; 95% confidence interval (CI): 1.471-1.565; HR, 1.902; 95% CI: 1.845-1.960, respectively] and validation sets (HR, 1.920, 95% CI: 1.989-3.310; HR, 1.989, 95% CI: 1.196-3.310, respectively). Patients with high TDs [>3] had significantly worse OS than those with low TDs [1-3] in both the training (P<0.001 by the log-rank test) and validation sets (P=0.007 by the log-rank test). Compared to CRC patients with negative TD combined with a low LNR, those with TD-positive combined with a high LNR had a 2.54-fold risk of death in the training set (HR, 2.538; 95% CI: 2.418-2.663) and a 3.90-fold risk in the validation set (HR, 3.897; 95% CI: 1.997-7.607). When combined with a high LNR, no differences were observed between patients with low TDs and high TDs in the two sets (P=0.12, log-rank test; P=0.72, log-rank test). Conclusions: The combined variable of LNR and TDs, regardless of the count of TDs, can accurately predict the risk of death in patients with CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.